PFIZER INC

PFE · NYSE · SIC 2834: Pharmaceutical Preparations · Market Cap: $158.3B · 75,000 employees
99
SEC Filings
$25.63
Close 2026-06-01
6
Transcripts
75,000
Employees

Business Summary

Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines and vaccines. Key products include Comirnaty (COVID-19 vaccine), Paxlovid (COVID-19 oral treatment), Prevnar family (pneumococcal vaccines), Vyndaqel family (transthyretin amyloid cardiomyopathy), and oncology products including antibody-drug conjugates acquired through Seagen. Pfizer operates across developed and emerging markets worldwide, with commercial operations spanning internal and alliance-based product portfolios.

Latest Stock Quote

PFE 2026-06-01 $25.63 O:$25.9 H:$25.91 L:$25.48 Vol:35.6M VWAP:$25.6429
origin leaf: b7eba7a9b3af9f25805d11d97e7e04d91c0ab0335bde548c9d8ab6f923b84c28

Next Earnings

expected 2026-08-14

Key People

NameRolePeriod
SteveAnalyst, Scala TD Cowen? – present
AlbertChairman of the Board, Chief Executive Officer, Bourla Pfizer Inc? – present

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionPFEdiscussed Regulation
topic_mentionPFEdiscussed Artificial Intelligence
topic_mentionPFEdiscussed Healthcare & Bio
topic_mentionPFEdiscussed Artificial Intelligence
topic_mentionPFEdiscussed Artificial Intelligence
topic_mentionPFEdiscussed Blockchain & Crypto
topic_mentionPFEdiscussed GPU & Accelerators
topic_mentionPFEdiscussed Networking
topic_mentionPFEdiscussed Regulation
topic_mentionPFEdiscussed Enterprise
topic_mentionPFEdiscussed Automotive
topic_mentionPFEdiscussed Healthcare & Bio
topic_mentionPFEdiscussed Platform & Ecosystem
metricPFE EPSreported $1.36
metricPFE EPSreported $3.22
guidancePFEguided expectations for revenues and Adjusted diluted EPS while also returning $9.8 billion
guidancePFEguided expect additional savings of $700 million
guidancePFEguided expected $5.7 billion
guidancePFEguided expect total company full year '26 revenues to be in the range of $59.5 billion
guidancePFEguided expected to trend lower again in '26 with revenues of approximately $5 billion

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310000078003-26-000026EDGAR105K words
2025-02-272024-12-310000078003-25-000054EDGAR—
2024-02-222023-12-310000078003-24-000039EDGAR—
2023-02-232022-12-310000078003-23-000024EDGAR—
2022-02-242021-12-310000078003-22-000027EDGAR—
2021-02-252020-12-310000078003-21-000038EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-05-052026-03-290000078003-26-000054EDGAR—
2025-11-042025-09-280000078003-25-000150EDGAR42K words
2025-08-052025-06-290000078003-25-000138EDGAR—
2025-05-052025-03-300000078003-25-000114EDGAR—
2024-11-042024-09-290000078003-24-000191EDGAR—
2024-08-052024-06-300000078003-24-000166EDGAR—
2024-05-082024-03-310000078003-24-000107EDGAR—
2023-11-082023-10-010000078003-23-000115EDGAR—
2023-08-092023-07-020000078003-23-000088EDGAR—
2023-05-102023-04-020001628280-23-017196EDGAR—
2022-11-092022-10-020000078003-22-000101EDGAR—
2022-08-102022-07-030000078003-22-000094EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-05-050000078003-26-000053EDGAR—
2026-04-270000078003-26-000044EDGAR—
2026-02-030000078003-26-000005EDGAR18K words
2025-12-160000078003-25-000167EDGAR—
2025-11-210001193125-25-291406EDGAR—
2025-11-130000078003-25-000159EDGAR—
2025-11-040000078003-25-000149EDGAR—
2025-08-050000078003-25-000136EDGAR—
2025-05-190001193125-25-122480EDGAR—
2025-04-290000078003-25-000111EDGAR—

99 total filings indexed. 71 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Earnings Transcripts

Call DateQuarterTitle
— PFE Earnings Call Transcript
— PFE Earnings Call Transcript
—Q1 FY2026PFE Q1 FY2026 Earnings Call Transcript
—Q4 FY2025PFE Q4 FY2025 Earnings Call Transcript
—Q4 FY2025PFE Q4 FY2025 Earnings Call Transcript
—Q4 FY2025PFE Q4 FY2025 Earnings Call Transcript

Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

developed-markets-(western-europe,-japan,-canada,-australia,-south-korea,-etc.) emerging-markets-(asia-ex-japan/south-korea,-latin-america,-eastern-europe,-africa,-middle-east,-turkey) united-states oncology vaccines internal-medicine covid-19-therapeutics-and-vaccines current-good-manufacturing-practices-(cgmp) mrna-(messenger-ribonucleic-acid)-platform biologics-license-application-(bla) new-drug-application-(nda) emergency-use-authorization-(eua)

Company Identity

CIK0000078003
TickerPFE
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedDE
HeadquartersNew York, NY
Websitehttps://www.pfizer.com
Listed1951-06-22

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: c7de278dae2a36343d5473cae110586d414f587079c281a86f827ffee9e0ec29
parent: 347edfde9b0ff2cfd4cdcdcb74f12d57a4cdc425a496868b7177e3db857cf3f2
content hash: 8c1299db74aaee8e9deba136d42daa8037991fff270640e60c932079372ad2d8
signed: 2026-06-02T19:02:16.141Z
sources: 25 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf